Articles tagged with Liver Cancer
A global survey revealed significant disruptions to liver cancer care during the COVID-19 pandemic, including delayed screenings and treatments. The survey found that 87% of participating cancer treatment centers modified their clinical practices, highlighting the need for continued investment in liver oncology nurses and education.
Researchers found a distinctive gut microbiome profile in people with liver cancer linked to non-alcoholic fatty liver disease (NAFLD) that modulates the immune response, promoting cancer survival. This discovery could lead to more effective preventative and therapeutic treatments for NAFLD-related liver cancer.
Researchers developed a risk score to prioritize liver cancer patients for transplantation, accounting for both cancer-related and non-cancer-related factors. The LiTES-HCC score predicts post-transplant survival for hepatocellular carcinoma patients, leading to more efficient allocation of livers.
Researchers at Massachusetts General Hospital have found that reprogramming the connective tissue microenvironment of a liver cancer can inhibit its progression and resistance to chemotherapy. Blocking placental growth factor (PlGF) with antibodies reduces production of connective tissue and increases survival in mice with liver cancer.
A new study found that tumors in the liver siphon off critical immune cells, rendering immunotherapy ineffective. However, coupling immunotherapy with radiotherapy restored immune cell function and led to better outcomes in mice. Researchers are now exploring potential clinical trials to understand the mechanisms at play.
A new treatment combination combining radiofrequency ablation and chemotherapy drug sunitinib significantly reduces tumor growth and extends the life span of mice with liver cancer. The therapy triggers an immune response to target and destroy liver cancer cells.
Osaka University researchers developed a technique to study liver cancer genes in lab mice, identifying a serum biomarker for effective treatment. The study found that FGF19-driven HCC is susceptible to lenvatinib treatment and a specific protein, ST6GAL1, can be used as a biomarker.
A major new study found that men with two copies of the faulty haemochromatosis genes are 10 times more likely to develop liver cancer by age 75 compared to the general population. Researchers call for routine early testing for the iron overload condition.
A recent study published by Shinshu University found that eating less can significantly reduce the risk of liver cancer caused by fatty liver. The research team observed a 41% decrease in liver tumors in mice with hepatitis C virus core gene, simply through dietary restriction.
A study analyzing US cancer data reveals patients from rural regions and lower-income households often have advanced liver cancer at diagnosis and face higher mortality rates. This highlights the need for targeted quality improvement interventions to address healthcare disparities affecting these populations.
Researchers discovered that liver tumors can harness the liver's powers to retrain the immune system and exert its influence on distant cancer cells. Adding a second checkpoint inhibitor in combination therapy may overcome this resistance and increase immunotherapy effectiveness.
Researchers used nationwide cancer mapping statistics to develop a mathematical model that reveals patterns of cancer incidence by remoteness. The study found cancers having higher incidence in remote areas include head and neck, liver, lung, oesophageal, cervical, and uterine cancers.
Researchers have identified a protein PPARα that regulates bile acid metabolism and suppresses the growth of cholangiocarcinoma in mice. The study provides new insights into liver cancer development and suggests potential therapeutic targets.
Scientists have identified a microRNA in obese mouse mothers that increases the odds of liver cancer in their offspring and throughout future generations. The study found that maternal obesity causes susceptibility to liver cancer in offspring, with the severity increasing over generations.
Researchers at Okayama University have developed a model showing how liver cancer stem cells are born from normal stem cells under specific environmental conditions. The study successfully established liver CSCs without genetic manipulation, providing a crucial tool for further research and potential targeted therapies.
A new treatment combination of atezolizumab and bevacizumab has significantly improved survival for people with hepatocellular carcinoma, reducing mortality risk by 42% and increasing cancer response rates. The therapy is being reviewed for FDA approval under a Real-Time Oncology Review pilot program.
A recent study by Florida Atlantic University found that racial inequalities in liver cancer deaths soared after the introduction of hepatitis C drugs in the US. The study showed a significant increase in mortality rates among black Americans, with excess relative deaths increasing from 27.8% to 45.4% between 1998 and 2016.
Researchers at Skoltech and MIT have developed a new combinatorial therapy for liver cancer using a siRNA approach coupled with lipid nanoparticle technology. This treatment caused a significant decrease in tumor load in a mouse model of hepatocellular carcinoma.
A new study found that exercise can prevent the development of liver cancer in obese mice with fatty liver disease. The research suggests that voluntary exercise exerts its protective effects via molecular signaling pathways, including tumor suppressor gene p53 and stress-activated protein kinase JNK1.
Researchers found that personalized cancer outreach using machine learning and targeted interventions can improve return on investment by 74-96%. The study used a randomized field experiment to analyze the effectiveness of different outreach programs, which varied in their impact depending on patient demographics and characteristics.
A new study found increasing global rates of liver cancer, particularly in people aged 30-59 years and 60 years and older, as well as a notable increase in men. The research, published in the journal Cancer, also revealed that hepatitis B vaccinations and obesity are associated with decreased rates of liver cancer in younger adults.
A recent analysis found that low-dose aspirin significantly reduces the risk of liver cancer and mortality from liver disease in high-risk adults. Over an 8-year follow-up, 4.0% of patients who took low-dose aspirin developed liver cancer, compared to 8.3% of nonusers.
Research finds that persistent NRF2 activation may contribute to enlarged liver and fatty liver diseases, affecting over 200 million worldwide. AKT inhibitors show promise in treating hepatomegaly.
Scientists at UNIGE discovered a protein, S100A11, that promotes inflammation and build-up of fibrous tissue in the liver, increasing cancer severity. The presence of S100A11 in blood may enable early detection through simple blood sampling, paving the way for targeted therapies.
A Cedars-Sinai team will investigate the interplay between dietary fat and fatty liver disease to understand how cancer spreads to the liver and find ways to block it. The study aims to identify key mechanisms that allow cancer to spread to the liver and develop potential treatments.
Research reveals that liver cancer tumors contain diverse sets of cells, affecting tumor growth and immune response. A single biopsy may mischaracterize a tumor's genetic makeup and immune cell infiltration.
A pooled analysis of nine studies involving over 750,000 adults found that recommended amounts of leisure-time physical activity were linked to a lower risk for seven cancers. The study suggests that people should aim for moderate- or vigorous-intensity activities for at least 2.5 to 5 hours/week to reduce cancer risk.
Researchers developed a mathematical model that uses RNA sequencing and bioinformatics to identify sudden transcriptomic switches in healthy liver tissue, turning them cancerous. The tool can predict tumor stages and prognosis for patients with liver cancer.
Researchers discover that non-cancerous liver cells around tumors have the capacity to kill nearby tumor cells when hyperactivated, leading to reduced tumor burden and longer survival in mice. The study identifies YAP and TAZ genes as driving this anti-tumor mechanism.
The incidence of liver cancer has tripled in the UK over the past 20 years, with the majority of cases diagnosed in men. The most deprived fifth of the population accounts for 25% of HCC cases, many of which have cirrhosis and are not treatable by surgery due to advanced scarring.
Researchers discovered a new protein, clathrin, involved in liver cancer development and progression. High levels of clathrin expression correlate with the activation of TGF-β pathway, promoting tumor growth and invasion.
Researchers at Charité - Universitätsmedizin Berlin developed a new diagnostic technique using tomoelastography to visualize liver tumor mechanical properties. The study found that hepatic malignancies contain tissues with both stiff and fluid properties, contrary to previous assumptions.
A new study published in Cancer Research found that excess fat in the liver impairs a tumor-suppressing protein named HNF4α, increasing cancer risk. The research provides potential mechanisms for the growing incidence of liver cancer linked to fatty liver disease.
A new study from National University of Singapore (NUS) researchers has demonstrated a potential method for treating advanced liver cancers like hepatocellular carcinoma (HCC). Targeting the JAK/STAT signalling pathway, they found that a class of small molecule drugs can effectively reduce cancer progression in preclinical models, with...
A new blood test can detect liver cancer and life-threatening vascular complications in diabetic patients with high accuracy. The test analyzes DNA in just a few drops of blood and has already shown promise in detecting other major cancers.
A large cohort study confirms that adding transarterial chemoembolization (TACE) to sorafenib improves survival rates in patients with advanced liver cancer, with median overall survival increasing by up to 26%. The treatment combination also shows similar tolerability compared to sorafenib alone.
Researchers from Osaka University have identified a gene, GREB1, as a key player in the development of hepatoblastoma. The study found that suppressing GREB1 production using antisense oligonucleotides significantly reduced tumor formation and cell proliferation in mouse liver cancer models.
Scientists found that Nqo1 is necessary for liver cancer cells' ability to thrive by activating key pathways. Blocking Nqo1 dramatically suppresses liver cancer cell proliferation.
A new study demonstrates that antiviral drugs for hepatitis C reduce liver-related deaths by nearly 50% in patients with a history of liver cancer. The finding reverses prior misconceptions about the relationship between hepatitis C and liver cancer recurrence.
A Northwestern University study found that many deadliest cancers, such as colon, lung, and liver cancer, receive significantly less nonprofit research funding than breast cancer, leukemia, and other well-funded types. This underfunding could impact research, drug development, and FDA approvals for these life-altering diseases.
Researchers discovered a cellular pathway linked to cancer that may benefit patients with hepatocellular carcinoma by reducing side effects and extending immunotherapy duration. The study found that blocking the IL-6/JAK1 pathway could resolve immunotherapy side effects and improve treatment outcomes.
Researchers identify a genetically aberrant protein that promotes rare form of liver cancer in adolescents and young adults. A targeted drug combination slows down uncontrolled cell growth, offering hope for improved treatment options.
A San Diego State University study finds that lumping all Hispanic-Americans together masks the differences in cancer outcomes. The study reveals subtle and sometimes significant differences in cancer risk among Cuban, Mexican, Puerto Rican, and Central and South American groups.
A large UK cohort study found poor oral health is strongly associated with a higher risk of hepatocellular carcinoma (HCC), the most common form of liver cancer. Poor oral health, including painful gums and loose teeth, was linked to an increased risk of HCC in patients.
A large cohort study found that blood transfusion during curative liver cancer surgery increases the risk of cancer recurrence by 23% and death by 55%. The extent to which blood transfusions worsen cancer outcomes is poorly understood.
Scientists created a human model using organoids to study the function of specific genes mutated in liver cancer. They found that BAP1 mutations change cell behavior, making them more likely to be invasive and forming malignant tumors. The newly developed model provides valuable insights into liver tumor development.
Researchers at Burrell College of Osteopathic Medicine found that New Mexicans with 10 common cancers have a significantly worse five-year survival rate. Hispanic populations along the U.S.-Mexico border fare even worse.
A new CRISPR/Cas9 system allows for precise gene knock-in in live cancer mouse models, improving efficiency and control over gene insertion. The system was used to model intrahepatic cholangiocarcinoma, a type of liver cancer, and successfully induced tumor formation in mice.
Researchers discovered that reduced adenosine kinase expression in the liver makes it more susceptible to carcinogenic damage and liver cancer. In a study published in Journal of Caffeine and Adenosine Research, scientists found that 64% of patients with liver cancer had lower adenosine kinase expression levels.
Researchers at CNIC have discovered that the protein p38gamma plays an essential role in initiating cell division in liver cells, making it a promising therapeutic target for liver cancer. The study found that inhibiting p38gamma slows down the development of liver cancer in mice, suggesting potential treatment options.
Rising liver cancer death rates in the US are largely confined to individuals with lower educational attainment, particularly men. The study highlights the need for targeted efforts to address the growing burden of liver cancer in lower socioeconomic groups.
A new study has uncovered important differences in the biological pathways that lead to cancer for alcoholic fatty liver disease compared to non-alcoholic fatty liver disease. The findings could benefit the more than 3 million people diagnosed with fatty liver disease each year, potentially leading to new cancer prevention strategies.
A study by UT Southwestern Medical Center researchers identified genetic mutations that accumulate in the adult liver and can promote tissue regeneration. The findings suggest that certain mutations provide liver cells with fitness advantages, allowing them to grow and survive better after environmental insults.
Researchers at CNIC have discovered a hormone called adiponectin that protects the liver from liver cancer, which affects more men than women. Adiponectin is produced in higher amounts in women and slim people, with levels declining after puberty in men.
Researchers at Oregon State University discovered that two hop-derived compounds inhibit liver and colon cancer cell growth effectively similar to xanthohumol. These non-estrogenic derivatives offer promising alternatives for future preclinical studies.
Research suggests that parasitic worms cause majority of cancers in poor countries due to chronic inflammation and toxic egg excretions. However, some species of helminths, like the 'hyper tapeworm', inhibit cancer growth and may even enhance host's immune response to tumors.
Researchers at the University of California San Diego School of Medicine have made breakthroughs in treating liver cancer with a combination immunotherapy approach. This therapy successfully suppresses tumor growth and induces complete remission in some mouse models, offering new hope for patients diagnosed with this devastating disease.
A pilot study published in PNAS detects early-stage liver cancer in HBV carriers with high accuracy, using cell-free DNA and protein biomarkers. The HCCscreen assay achieves a 17% positive predictive value, 100% sensitivity, and 94% specificity.
Researchers at University of Pennsylvania School of Medicine found that hepatocytes orchestrate cancer spread to liver by activating protein STAT3, which increases production of SAA proteins. This 'soil' allows cancer cells to 'seed' and establish in the liver.
Researchers identify a new molecular pathway that suggests rapamycin, an anti-rejection medication, could be repurposed to treat certain liver cancers with β-catenin mutations. The study found that tumors are 'mTOR addicted' and can be inhibited by rapamycin, offering a precision medicine approach for improved treatment success.